Scribe Therapeutics stands out in the field of genetic medicine with its proprietary CRISPR by Design™ approach, which is touted as the most advanced platform for CRISPR-based genetic medicine. The company's integrated technologies are specifically designed for therapeutic use, offering key advantages such as novel viral and non-viral delivery technologies for in vivo genetic medicine, and highly active editing activities capable of targeting and eliminating the root causes of diseases. Moreover, Scribe's commitment to exceptional specificity within the genome ensures therapeutic precision and allele-specific targeting, setting a high bar for industry standards.